News

Shire has received approval from the FDA for Intuniv (guanfacine) extended release tablets for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17

Allos Therapeutics has announced that FDA’s Oncologic Drugs Advisory Committee (ODAC) voted that the response rate and duration of response observed with FOLOTYNTM (pralatrexate) are likely to predict

Bristol-Myers Squibb has announced that FDA has accepted its submission of a biologic license application for belatacept, for filing and review. Belatacept is in ongoing phase III development

BioSpecifics Technologies has declared results of the pivotal CORD I phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum), a novel biologic for the nonsurgical treatment of Dupuytren’s

Novartis presented data at the European Society of Cardiology (ESC) Congress in Barcelona, Spain, which demonstrated that the addition of the angiotensin receptor blocker (ARB) Diovan (valsartan) to

PTC Therapeutics (PTC) has entered into an exclusive research collaboration and licensing agreement with Roche, for the development of orally bioavailable small molecules utilizing PTC’s technology – Gene

Abbott has signed a definitive agreement to acquire Visiogen for $400m in cash, providing the company with a next-generation accommodating intraocular lens (IOL) technology to address presbyopia for

PTC Therapeutics (PTC) has reported that Celgene has exercised its option to collaborate on advancing drug discovery efforts on an oncology target addressed through the application of PTC’s

The Blanchette Rockefeller Neurosciences Institute (BRNI) has entered into an agreement with a group of neurological specialists (Brain Injury Group), to examine possible confluences of the Group’s work